Skip to main content

Regeneron Pharmaceuticals, Inc.

corporate_fare Company Profile

Regeneron Pharmaceuticals, Inc.

REGN·NASDAQ·Life Sciences·CIK 0000872589

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and sells medicines globally for various diseases. The company develops potential treatments for eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and hematologic conditions. Its product portfolio includes EYLEA injections for wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity. It also offers Dupixent injection for atopic dermatitis and asthma, Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent injection for heterozygous familial hypercholesterolemia (HoFH), and Kevzara solution for rheumatoid arthritis. Regeneron has a license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA. It collaborates with Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for eye and central nervous system diseases. The company also works with Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development focused on neurological and muscular diseases. Regeneron has an agreement with Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor. Additionally, it collaborates with Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency, and with Telix Pharmaceuticals Limited for radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for REGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for REGN spans 8-K, 13F-HR, 10-Q.

Recent high-impact activity:

  • FDA Approves Livsayis, First siRNA Therapy for Generalized Myasthenia Gravis
  • Single-Dose CIDEB siRNA Cuts Liver Fat Up to 80% in MASLD, Published in NEJM
  • Regeneron Hits 52-Week High as Q3 EPS Tops Consensus by 24%
  • Regeneron Q3 Revenue Jumps 36% to $5.1B; Non-GAAP EPS Up 70% to $20.07, Guidance Raised
  • Regeneron Posts $18.45 Q3 EPS as Shares Sit Near 52-Week High

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$14.34B
Net Income
$4.5B
Diluted EPS
$41.48
Op. Cash Flow
$4.98B
Free Cash Flow
$4.08B
Operating Income
$3.58B
Cash & Equivalents
$3.12B
Total Debt
$1.99B
Debt / Equity
0.06×
Net Margin
31.4%
Shares Outstanding
104.6M sh
Source: 10-K · filed 2026-02-04 · accession 0000872589-26-000008

Short Interest & Short Volume

2.73 days to cover

FINRA reported short interest of 2,217,114 shares in REGN as of the October 30, 2026 settlement, a 3.9% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 38.9% of REGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,217,114 shares as of October 30, 2026
Change vs prior period▲ 3.9%
Days to cover2.73 at avg daily volume of 810,850
Daily short volume (FINRA facilities)38.9% of 257,389 shares on November 20, 2026
5-day average short volume43.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with R →
$920.59 -0.01% today
52-week range · as of 2026-10-30 $591.52 – $920.59
Market cap
$95.23B
Volume
878.3K (1.0× avg)
3-mo avg 923.8K
Live data · 2026-11-21 05:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed REGN - Latest Insights

REGN
Nov 18, 2026, 6:06 PM EST
Source: Reuters
Importance Score:
9
Price at Filing: $942.00
Real-time Price: $920.59 info
Change: -$21.41 (-2%) info
Market Cap: $95.228B info
REGN
Nov 08, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $900.00
Real-time Price: $920.59 info
Change: +$20.59 (+2%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 12:34 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $910.52
Real-time Price: $920.59 info
Change: +$10.07 (+1%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $856.00
Real-time Price: $920.59 info
Change: +$64.59 (+8%) info
Market Cap: $95.228B info
REGN
Oct 30, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $835.00
Real-time Price: $920.59 info
Change: +$85.59 (+10%) info
Market Cap: $95.228B info
REGN
Oct 12, 2026, 12:06 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $764.45
Real-time Price: $920.59 info
Change: +$156.14 (+20%) info
Market Cap: $95.228B info
REGN
Oct 06, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $721.96
Real-time Price: $920.59 info
Change: +$198.63 (+28%) info
Market Cap: $95.228B info
REGN
Oct 01, 2026, 12:46 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $728.38
Real-time Price: $920.59 info
Change: +$192.21 (+26%) info
Market Cap: $95.228B info
REGN
Oct 01, 2026, 11:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $734.48
Real-time Price: $920.59 info
Change: +$186.11 (+25%) info
Market Cap: $95.228B info
REGN
Oct 01, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Updated Oct 1, 10:42 AM ET — Sanofi shares climbed as much as 3.7% and Regeneron opened 1.1% higher after the deal was announced.
Price at Filing: $759.00
Real-time Price: $920.59 info
Change: +$161.59 (+21%) info
Market Cap: $95.228B info
REGN
Oct 01, 2026, 2:34 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $759.00
Real-time Price: $920.59 info
Change: +$161.59 (+21%) info
Market Cap: $95.228B info
REGN
Sep 30, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $753.00
Real-time Price: $920.59 info
Change: +$167.59 (+22%) info
Market Cap: $95.228B info
REGN
Aug 19, 2026, 1:58 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $840.51
Real-time Price: $920.59 info
Change: +$80.09 (+10%) info
Market Cap: $95.228B info
REGN
Aug 07, 2026, 4:11 PM EDT
Filing Type: 13F-HR
Importance Score:
7
Price at Filing: $784.36
Real-time Price: $920.59 info
Change: +$136.23 (+17%) info
Market Cap: $95.228B info
REGN
Aug 06, 2026, 11:31 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $763.55
Real-time Price: $920.59 info
Change: +$157.04 (+21%) info
Market Cap: $95.228B info
REGN
Jul 30, 2026, 6:52 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $724.00
Real-time Price: $920.59 info
Change: +$196.59 (+27%) info
Market Cap: $95.228B info
REGN
Jul 30, 2026, 6:50 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $717.00
Real-time Price: $920.59 info
Change: +$203.59 (+28%) info
Market Cap: $95.228B info
REGN
Jul 30, 2026, 6:48 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $717.00
Real-time Price: $920.59 info
Change: +$203.59 (+28%) info
Market Cap: $95.228B info
REGN
Jul 30, 2026, 2:12 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $700.06
Real-time Price: $920.59 info
Change: +$220.53 (+32%) info
Market Cap: $95.228B info
REGN
Jul 21, 2026, 7:00 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $674.90
Real-time Price: $920.59 info
Change: +$245.69 (+36%) info
Market Cap: $95.228B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets